A study with 67 CRC patients demonstrated that 100% of the patients with negative expression of PTEN exhibited disease progression following treatment with cetuximab, whereas 30% of the PTEN expression patients showed reduced disease progression [78]. The gene discussed is PTEN; the disease is colorectal carcinoma.